Breast cancer
ESMO 2021: Instability in HER2 expression over disease progression opens up treatment options
HER2-low expression is highly unstable during breast cancer evolution suggesting that biopsies of locoregional relapses or distant metastases might reveal potentially new therapeutic opportunities for some patients, research suggests.
Presenting at ESMO Breast Cancer 2021, Dr Federica Miglietta said access to...
HER2-low expression is highly unstable during breast cancer evolution suggesting that biopsies of locoregional relapses or distant metastases might reveal...
